Adaptimmune Therapeutics PLC
ADAPYNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for ADAPY. That does not mean none is planned.
Get an email about ADAPY's next catalysts
Track Adaptimmune Therapeutics (ADAPY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park.
Website| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NYESO-1c259 T cells | Phase 2 | Ovarian Cancer | - | - |
Frequently asked questions
What is in Adaptimmune Therapeutics PLC's drug pipeline?β
CatalystAlert tracks 1 drug candidate in Adaptimmune Therapeutics PLC's (ADAPY) pipeline across Phase 2. Its lead program is NYESO-1c259 T cells (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Adaptimmune Therapeutics PLC's next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Adaptimmune Therapeutics PLC (ADAPY) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track ADAPY biotech catalysts?β
Add ADAPY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Adaptimmune Therapeutics PLC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
